Molecular Mechanism of Alzheimer's Disease: Aβ -amyloid protein deposition, abnormal phosphorylation of tau protein and neurofibrillary tangles
DOI:
https://doi.org/10.54097/7n5xb971Keywords:
Pathological mechanisms, Neuroinflammation, Nano-delivery, Nasal administration, Targeted therapy.Abstract
Alzheimer's disease (AD) is a prevalent neurodegenerative disorder that seriously endangers the physical and mental health of the elderly population. Currently, the molecular pathogenic mechanism of this disease has not been fully elucidated, and there are limitations in clinical treatment methods, making it difficult to curb the progression of the disease at its root. This article systematically analyzed the interactive effects of the three core pathological mechanisms in AD, namely Aβ deposition, excessive phosphorylation of Tau protein, and neuroinflammation, and reviewed the advantages and disadvantages of traditional interventions, nano-delivery carriers, and nasal administration as new treatment technologies. The results show that the pathological process of AD is dominated by a multi-dimensional interactive network, and the APOE4 gene and chronic neuroinflammation play a key role in upstream regulation. Simply removing pathological proteins cannot stop disease progression, while targeted precise intervention such as p-tau217 and ceRNA regulatory networks show significant potential. This study clarified the multi-factor interwoven pathological regulatory mechanism of AD, complemented the cognitive limitations of single pathological research, and provided theoretical support for the development of early screening markers and precise targeted treatment. The causal relationship between neuroinflammation and pathological protein lesions is still unclear at present. Future research can focus on the pathological dynamic changes during the disease latency period, optimize multi-target combined treatment plans, improve nano-nasal administration technology, and promote the clinical translation and application of new treatment strategies.
Downloads
References
[1] Huang P, Fang R, Li BY, et al. Exercise-related changes of networks in aging and mild cognitive impairment brain. Frontiers in Aging Neuroscience, 2016, 8:47. DOI:10.3389/fnagi.2016.00047. DOI: https://doi.org/10.3389/fnagi.2016.00047
[2] Cheng J, Ji X, He L, et al. Epidemiological characteristics and factors associated with Alzheimer's disease and mild cognitive impairment among the elderly in urban and rural areas of Hubei Province. Journal of Clinical Medicine, 2022, 12(1):28. DOI:10.3390/jcm12010028. DOI: https://doi.org/10.3390/jcm12010028
[3] Heneka MT, van der Flier WM, Jessen F, et al. Neuroinflammation in Alzheimer disease. Nature Reviews Immunology, 2025, 25(5):321-352. DOI:10.1038/s41577-024-01104-7. DOI: https://doi.org/10.1038/s41577-024-01104-7
[4] Passeri E, Elkhoury K, Morsink M, et al. Alzheimer's disease: treatment strategies and their limitations. International Journal of Molecular Sciences, 2022, 23(22):13954. DOI:10.3390/ijms232213954. DOI: https://doi.org/10.3390/ijms232213954
[5] Zhang H, Wei W, Zhao M, et al. Interaction between Aβ and tau in the pathogenesis of Alzheimer's disease. International Journal of Biological Sciences, 2021, 17(9):2181-2192. DOI:10.7150/ijbs.57078. DOI: https://doi.org/10.7150/ijbs.57078
[6] Valiukas Z, Tangalakis K, Apostolopoulos V, et al. Microglial activation states and their implications for Alzheimer's disease. The Journal of Prevention of Alzheimer's Disease, 2025, 12(1):100013. DOI:10.1016/j.tjpad.2024.100013. DOI: https://doi.org/10.1016/j.tjpad.2024.100013
[7] Jucker M, Walker LC. Alzheimer's disease: from immunotherapy to immunoprevention. Cell, 2023, 186(20):4260-4270. DOI:10.1016/j.cell.2023.08.021. DOI: https://doi.org/10.1016/j.cell.2023.08.021
[8] Zheng H, Sun H, Cai Q, et al. The enigma of tau protein aggregation: mechanistic insights and future challenges. International Journal of Molecular Sciences, 2024, 25(9):4969. DOI:10.3390/ijms25094969. DOI: https://doi.org/10.3390/ijms25094969
[9] Zhang D, Zhang W, Ming C, et al. P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy. Neuron, 2024, 112(10):1676-1693.e12. DOI:10.1016/j.neuron.2024.02.017. DOI: https://doi.org/10.1016/j.neuron.2024.02.017
[10] Singh D. Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimer's disease. Journal of Neuroinflammation, 2022, 19(1):206. DOI:10.1186/s12974-022-02565-0. DOI: https://doi.org/10.1186/s12974-022-02565-0
[11] Parhizkar S, Holtzman DM. APOE-mediated neuroinflammation and neurodegeneration in Alzheimer's disease. Seminars in Immunology, 2022, 59:101594. DOI:10.1016/j.smim.2022.101594. DOI: https://doi.org/10.1016/j.smim.2022.101594
[12] Zhang P, Ma Y. Screening of biomarkers related to Alzheimer's disease based on construction of a ceRNA regulation network. Neurological Research, 2026, 48(2):209-218. DOI: https://doi.org/10.1080/01616412.2025.2529563
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

